Mirum Pharmaceuticals (MIRM) CEO sells 20,000 shares after exercising options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Mirum Pharmaceuticals CEO Christopher Peetz exercised stock options for 20,000 shares of common stock at $2.936 per share and sold 20,000 shares in open-market transactions on July 6, 2026 under a Rule 10b5-1 Plan. Following these trades, he holds 196,019 shares directly and 187,500 shares indirectly through The Peetz Family Trust.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 20,000 shares ($2,445,382)
Net Sell
7 txns
Insider
Peetz Christopher
Role
CHIEF EXECUTIVE OFFICER
Sold
20,000 shs ($2.45M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 20,000 | $0.00 | -- |
| Exercise | Common Stock | 20,000 | $2.936 | $59K |
| Sale | Common Stock | 12,134 | $121.65 | $1.48M |
| Sale | Common Stock | 4,181 | $122.34 | $512K |
| Sale | Common Stock | 1,975 | $123.74 | $244K |
| Sale | Common Stock | 1,710 | $124.79 | $213K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 108,487 shares (Direct, null);
Common Stock — 214,309 shares (Direct, null);
Common Stock — 187,500 shares (Indirect, By The Peetz Family Trust)
Footnotes (1)
- Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026. The weighted average sale price for the transaction reported was $121.65, and the range of prices were between $121.11 and $122.105. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $122.34, and the range of prices were between $122.13 and $123.1125. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $123.74, and the range of prices were between $123.24 and $124.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $124.79, and the range of prices were between $124.27 and $124.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The stock option is fully vested.
Key Figures
Shares sold: 20,000 shares
Sale prices: $121.11–$124.94/share
Options exercised: 20,000 shares
+5 more
8 metrics
Shares sold
20,000 shares
Open-market sales on July 6, 2026
Sale prices
$121.11–$124.94/share
Reported price ranges with weighted averages
Options exercised
20,000 shares
Employee Stock Option exercise on July 6, 2026
Exercise price
$2.936/share
Conversion or exercise price for 20,000 options
Direct holdings after
196,019 shares
Common stock held directly after transactions
Indirect holdings
187,500 shares
Held by The Peetz Family Trust
Rule 10b5-1 plan date
March 2, 2026
Adoption date for pre-planned trading program
Option expiration
March 11, 2029
Original expiration date of exercised option grant
Key Terms
Rule 10b5-1 Plan, Employee Stock Option (right to buy), weighted average sale price, open-market sale, +1 more
5 terms
Rule 10b5-1 Plan regulatory
"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Employee Stock Option (right to buy) financial
"security_title: "Employee Stock Option (right to buy)" with 20,000.0000 shares exercised."
weighted average sale price financial
"The weighted average sale price for the transaction reported was $121.65, and the range of prices were between $121.11 and $122.105."
open-market sale financial
"transaction_action: "open-market sale" with transaction_code "S" for common stock."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
fully vested financial
"The stock option is fully vested."
FAQ
What insider transactions did Mirum Pharmaceuticals (MIRM) CEO report on July 6, 2026?
Mirum Pharmaceuticals CEO Christopher Peetz exercised options for 20,000 shares at $2.936 and sold 20,000 common shares in open-market transactions on July 6, 2026. These trades were reported in a Form 4 insider filing with updated post-transaction holdings.
What stock options did the Mirum Pharmaceuticals (MIRM) CEO exercise in this Form 4?
The CEO exercised an Employee Stock Option for 20,000 Mirum Pharmaceuticals shares at a conversion or exercise price of $2.936 per share. The option is fully vested and was originally scheduled to expire on March 11, 2029, according to the filing details and footnotes.